$0.88 0.00 (%) Galectin Therapeutics Inc - NASDAQ

Dec. 7, 2016 | 11:08 AM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. 5 Biotech Stocks to Watch as Interest in NASH Increases

    TalkMarkets | Sep. 22, 2016 | 13:45PM EST
  2. Morning Market Losers

    Benzinga | Nov. 20, 2015 | 10:06AM EST
  3. Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference

    Benzinga | Oct. 7, 2015 | 15:09PM EST
  4. Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz ...

    GuruFocus | Oct. 6, 2015 | 23:03PM EST
  5. Benzinga's Top Initiations

    Benzinga | Sep. 21, 2015 | 09:11AM EST
  6. Galectin Therapeutics Announces Start of Phase 2 Clinical Trial with GR-MD-02 in NASH with Advanced Fibrosis

    Benzinga | Sep. 16, 2015 | 06:58AM EST
  7. Mid-Day Market Update: Thursday's Movers, China, Tesla And More

    Benzinga | Aug. 13, 2015 | 12:09PM EST
  8. Morning Market Gainers

    Benzinga | Aug. 13, 2015 | 08:45AM EST
  9. Morning Market Gainers

    Benzinga | Jan. 7, 2015 | 09:38AM EST
  10. Stocks Hitting 52-Week Lows

    Benzinga | Dec. 24, 2014 | 10:12AM EST
  11. MLV & Co Has Positive Outlook On Galectin Therapeutics Inc

    Benzinga | Sep. 16, 2014 | 08:56AM EST
  12. UPDATE: Aegis Capital Downgrades Galectin Therapeutics

    Benzinga | Aug. 1, 2014 | 11:26AM EST
  13. Galectin Issues Statement on Yesterday's Sell Off, Says Attributed To Negative Social Media Posts and Misinterpretation

    Benzinga | Jul. 30, 2014 | 08:09AM EST
  14. Morning Market Losers

    Benzinga | Jul. 29, 2014 | 08:54AM EST
  15. Galectin Offers Results in Preclinical Model of GR-MD-02, Results Show Significant Disease Improvement

    Benzinga | Jun. 23, 2014 | 07:06AM EST
  16. Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02

    Benzinga | Apr. 23, 2014 | 07:02AM EST
  17. Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis; Exoects GR-MD-02 Phase 1 Cohort 2 Result at End of July

    Benzinga | Apr. 17, 2014 | 09:23AM EST
  18. MLV & Co Expects Positive News from Galectin Therapeutics

    Benzinga | Apr. 1, 2014 | 08:03AM EST
  19. Benzinga's Volume Movers

    Benzinga | Mar. 25, 2014 | 09:26AM EST
  20. Fatty Liver Disease Should Keep Stocks Moving In 2014

    IBD | Mar. 7, 2014 | 17:02PM EST
  21. Galectin Therapeutics Complet Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Patients with NASH

    Benzinga | Jan. 13, 2014 | 08:05AM EST
  22. Market Wrap For January 10: Job Growth Weak, But Unemployment Falls

    Benzinga | Jan. 10, 2014 | 16:53PM EST
  23. Benzinga's Volume Movers

    Benzinga | Jan. 10, 2014 | 10:26AM EST
  24. Galectin Announces Early Warrant Exercise by 10X Fund, Issues Update on Cash Position

    Benzinga | Oct. 17, 2013 | 07:09AM EST
  25. UPDATE: Ascendiant Capital Initiates Coverage on Galectin Therapeutics on Intriguing Speculative Short-Cap Investment Story

    Benzinga | Oct. 7, 2013 | 09:55AM EST
  26. Benzinga's Top Initiations

    Benzinga | Oct. 7, 2013 | 06:49AM EST
  27. Benzinga's Volume Movers

    Benzinga | Sep. 12, 2013 | 09:43AM EST
  28. Morning Market Movers

    Benzinga | Sep. 12, 2013 | 09:11AM EST
  29. Benzinga's Volume Movers

    Benzinga | Sep. 11, 2013 | 09:45AM EST
  30. UPDATE: Aegis Capital Raises PT on Galectin Therapeutics Following Valuation Update

    Benzinga | Aug. 19, 2013 | 10:26AM EST
  31. Morning Market Movers

    Benzinga | Aug. 12, 2013 | 09:13AM EST
  32. Galectin Therapeutics Reports FDA Fast Track Designation for GR-MD-02

    Benzinga | Aug. 12, 2013 | 07:04AM EST
  33. Galectin Therapeutics Says Anti-Galectin Drug Effective in Preclinical Studies

    Benzinga | Jan. 22, 2013 | 02:04AM EST
  34. Galectin Therapeutics Names Shlevin COO

    Benzinga | Aug. 29, 2012 | 02:01AM EST
  35. Galectin Therapeutics Receives U.S. Patent for Potential Ground-Breaking Treatment for Chronic Liver Disease with Fibrosis and Cirrhosis

    Benzinga | Jul. 23, 2012 | 02:48AM EST
  36. UPDATE: Dawson James Reiterates Buy Rating, Lowers PT on Galectin Therapeutics

    Benzinga | Jul. 6, 2012 | 04:00AM EST
  37. ProShares Trust Ultra VIX Short Term Futures ETF, CTC Media Among Stocks hitting 52-Week Lows Tuesday

    FoxBusiness | Jul. 3, 2012 | 05:31AM EST
Trading Center